Table 1.
Laboratory data.
| Before the administration of chemotherapy | After third cycle of chemotherapy | The onset of acute exacerbation | |
|---|---|---|---|
| WBC (/μL) | 11,600 | 6200 | 13,400 |
| HGB (g/dL) | 14.2 | 9.8 | 12.6 |
| PLT (x104 /μL) | 38.4 | 21.4 | 25.9 |
| AST (U/L) | 12 | 18 | 16 |
| ALT (U/L) | 11 | 11 | 18 |
| LDH (U/L) | 241 | 216 | 343 |
| T-bil (mg/dL) | 0.4 | 0.6 | 0.6 |
| CK (U/L) | 56 | 26 | 16 |
| BUN (mg/dL) | 13 | 16 | 16 |
| Cr (mg/dL) | 0.72 | 0.92 | 0.68 |
| Na (mEq/L) | 139 | 139 | 141 |
| K (mEq/L) | 4.1 | 4.1 | 3.9 |
| Cl (mEq/L) | 103 | 100 | 103 |
| CRP (mg/dL) | 0.93 | 6.81 | 7.80 |
| KL-6 (U/mL) | 1161 | 797 | 1559 |
| SP-D (ng/mL) | 84.4 | N.E. | 141 |
| ANA (dils) | 40 | N.E. | <40 |
| Anti-CCP Ab (U/mL) | N.E. | N.E. | <0.6 |
| Anti-ARS Ab (Index) | 35.7a | N.E. | 129 |
| MPO-ANCA (U/mL) | N.E. | N.E. | <1.0 |
| PR3-ANCA (U/mL) | N.E. | N.E. | <1.0 |
N.E.; not examined.
a
Retrospectively evaluated after the development of ICI-related pneumonitis.